Auranofin
"Auranofin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
| Descriptor ID |
D001310
|
| MeSH Number(s) |
D02.691.675.249.150
|
| Concept/Terms |
Ridauran- Ridauran
- Robapharm Brand of Auranofin
- Auranofin Robapharm Brand
Crisinor- Crisinor
- Rubio Brand of Auranofin
- Auranofin Rubio Brand
Ridaura- Ridaura
- SmithKline Beecham Brand of Auranofin
- Recordati Brand of Auranofin
- Auranofin Recordati Brand
- Yamanouchi Brand of Auranofin
- Auranofin Yamanouchi Brand
|
Below are MeSH descriptors whose meaning is more general than "Auranofin".
Below are MeSH descriptors whose meaning is more specific than "Auranofin".
This graph shows the total number of publications written about "Auranofin" by people in UAMS Profiles by year, and whether "Auranofin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Auranofin" by people in Profiles over the past ten years.
-
Pessetto ZY, Chen B, Alturkmani H, Hyter S, Flynn CA, Baltezor M, Ma Y, Rosenthal HG, Neville KA, Weir SJ, Butte AJ, Godwin AK. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget. 2017 Jan 17; 8(3):4079-4095.